Results 181 to 190 of about 64,020 (335)

Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4529-4545, June 2026.
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley   +1 more source

Chronic Glycaemic Control Modulates the Relationship Between GIP and Glucagon Secretion Following Oral and Enteral Nutrients in Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5287-5293, June 2026.
ABSTRACT Aims Glucose‐dependent insulinotropic polypeptide (GIP) may exert both insulinotropic and glucagonotropic effects. While its insulinotropic action is reportedly attenuated or abolished with worsening of glycaemic control in type 2 diabetes (T2D), the relationship between GIP and glucagon secretion across different levels of glycaemic control ...
Zhenxi Wang   +7 more
wiley   +1 more source

Plant‐Produced Viral Nanoparticles Decorated with Nanobodies Against HER2 Improve Retention and Recruitment of Immune Cells in Solid Tumors

open access: yesAdvanced Healthcare Materials, Volume 15, Issue 18, 15 May 2026.
Potato virus X is a filamentous RNA plant virus that can be engineered into a molecular tool for cancer therapy. We produced genetically‐encoded virus‐derived nanoparticles decorated with nanobodies targeting cancer cell receptors, epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 (HER2).
Enrique Lozano‐Sanchez   +4 more
wiley   +1 more source

How does type 2 diabetes modify the risk of Alzheimer's disease?

open access: yesAlzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract Type 2 diabetes (T2D) and Alzheimer's disease (AD) are both increasing exponentially worldwide. T2D has also been identified as one of 14 modifiable risk factors for dementia, but the mechanism is unknown. T2D could promote dementia via vascular or AD neuropathological changes, and mechanistic hypotheses include central insulin resistance and ...
G. T. Sutherland   +7 more
wiley   +1 more source

Glycemic, insulinemic and incretin responses after oral trehalose ingestion in healthy subjects [PDF]

open access: yes, 2017
Akiko Mizote   +9 more
core   +1 more source

Ontogeny of Placental FcRn Protein During Human and Animal Pregnancy to Inform Developmental Toxicity Testing

open access: yesBirth Defects Research, Volume 118, Issue 5, May 2026.
ABSTRACT Introduction Species differences exist in Fc domain‐containing molecule transfer/biodistribution to the embryo‐fetus during pregnancy. Placentation was reviewed and placental neonatal Fc receptor (FcRn) quantitation in the chorioallantoic placenta (CAP) and/or inverted yolk sac placenta (InvYSP) was investigated across species throughout ...
Christopher J. Bowman   +11 more
wiley   +1 more source

Oncogenic driver and therapeutic target: Prolactin signalling axis in retroperitoneal sarcoma

open access: yesClinical and Translational Medicine, Volume 16, Issue 5, May 2026.
Retroperitoneal sarcoma cells can secrete prolactin into the bloodstream, inducing hyperprolactinaemia, which subsequently triggers metabolic reprogramming, such as glucose metabolism. SOX4 can function as a transcription factor that facilitates PRL transcription.
Fu'an Xie   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy